346 related articles for article (PubMed ID: 18086519)
21. The cost of treating patients with COPD in Denmark--a population study of COPD patients compared with non-COPD controls.
Bilde L; Rud Svenning A; Dollerup J; Baekke Borgeskov H; Lange P
Respir Med; 2007 Mar; 101(3):539-46. PubMed ID: 16889949
[TBL] [Abstract][Full Text] [Related]
22. Cost impact of COPD in Japan: opportunities and challenges?
Nishimura S; Zaher C
Respirology; 2004 Nov; 9(4):466-73. PubMed ID: 15612957
[TBL] [Abstract][Full Text] [Related]
23. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991.
Jacobson L; Hertzman P; Löfdahl CG; Skoogh BE; Lindgren B
Respir Med; 2000 Mar; 94(3):247-55. PubMed ID: 10783936
[TBL] [Abstract][Full Text] [Related]
24. Chronic obstructive pulmonary disease patients with psychiatric disorders are at greater risk of exacerbations.
Laurin C; Labrecque M; Dupuis G; Bacon SL; Cartier A; Lavoie KL
Psychosom Med; 2009 Jul; 71(6):667-74. PubMed ID: 19561164
[TBL] [Abstract][Full Text] [Related]
25. Costs of COPD exacerbations in the emergency department and inpatient setting.
Dalal AA; Shah M; D'Souza AO; Rane P
Respir Med; 2011 Mar; 105(3):454-60. PubMed ID: 20869226
[TBL] [Abstract][Full Text] [Related]
26. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
[TBL] [Abstract][Full Text] [Related]
27. Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes).
Dal Negro RW; Tognella S; Tosatto R; Dionisi M; Turco P; Donner CF
Respir Med; 2008 Jan; 102(1):92-101. PubMed ID: 17881206
[TBL] [Abstract][Full Text] [Related]
28. [Retrospective analysis of direct costs of hospital treatment of chronic obstructive pulmonary disease exacerbations].
Jahnz-Rózyk K; Targowski T; From S; Płusa T
Pol Merkur Lekarski; 2004 May; 16 Suppl 1():91-4. PubMed ID: 15524028
[TBL] [Abstract][Full Text] [Related]
29. Substitutive "hospital at home" versus inpatient care for elderly patients with exacerbations of chronic obstructive pulmonary disease: a prospective randomized, controlled trial.
Aimonino Ricauda N; Tibaldi V; Leff B; Scarafiotti C; Marinello R; Zanocchi M; Molaschi M
J Am Geriatr Soc; 2008 Mar; 56(3):493-500. PubMed ID: 18179503
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of a disease management program for chronic obstructive pulmonary disease.
Dewan NA; Rice KL; Caldwell M; Hilleman DE
COPD; 2011 Jun; 8(3):153-9. PubMed ID: 21513435
[TBL] [Abstract][Full Text] [Related]
31. The cost of COPD exacerbations: a university hospital--based study in Greece.
Geitona M; Hatzikou M; Steiropoulos P; Alexopoulos EC; Bouros D
Respir Med; 2011 Mar; 105(3):402-9. PubMed ID: 20970310
[TBL] [Abstract][Full Text] [Related]
32. [Estimation of direct medical costs of chronic obstructive pulmonary disease over 12 months].
Stâmbu I; Stoicescu IP
Pneumologia; 2013; 62(2):86-92. PubMed ID: 23894789
[TBL] [Abstract][Full Text] [Related]
33. The outpatient treatment of deep vein thrombosis delivers cost savings to patients and their families, compared to inpatient therapy.
Rodger MA; Gagné-Rodger C; Howley HE; Carrier M; Coyle D; Wells PS
Thromb Res; 2003; 112(1-2):13-8. PubMed ID: 15013267
[TBL] [Abstract][Full Text] [Related]
34. [Analysis on direct economic burden of community COPD patients and its influence factors in Chengdu].
Zhang B; Zhang Y; Yang J; Liu X
Wei Sheng Yan Jiu; 2007 Nov; 36(6):706-10. PubMed ID: 18303632
[TBL] [Abstract][Full Text] [Related]
35. Economic analysis in admitted patients with acute exacerbation of chronic obstructive pulmonary disease.
Chen YH; Yao WZ; Cai BQ; Wang H; Deng XM; Gao HL; Huang JS; Wang XM
Chin Med J (Engl); 2008 Apr; 121(7):587-91. PubMed ID: 18466676
[TBL] [Abstract][Full Text] [Related]
36. Resource utilization and costs of treating severe rotavirus diarrhea in young Mexican children from the health care provider perspective.
Granados-García V; Velázquez-Castillo R; Garduño-Espinosa J; Torres-López J; Muñoz-Hernández O
Rev Invest Clin; 2009; 61(1):18-25. PubMed ID: 19507471
[TBL] [Abstract][Full Text] [Related]
37. Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study.
Lisspers K; Johansson G; Jansson C; Larsson K; Stratelis G; Hedegaard M; Ställberg B
Respir Med; 2014 Sep; 108(9):1345-54. PubMed ID: 25002194
[TBL] [Abstract][Full Text] [Related]
38. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
39. [Active tobacco smoking as determinant of costs of inpatient treatment of COPD exacerbations].
Targowski T; Jahnz-Rózyk K; From S; Płusa T
Przegl Lek; 2004; 61(10):1049-51. PubMed ID: 15794248
[TBL] [Abstract][Full Text] [Related]
40. Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.
Donohue JF; Hanania NA; Ciubotaru RL; Noe L; Pasta DJ; Schaefer K; Claus R; Andrews WT; Roach J
Clin Ther; 2008; 30 Spec No():989-1002. PubMed ID: 18640474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
